Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study

NCT02457858 | Completed Phase 1 DMC

• 1 other identifier: Pro00045961
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, the investigators hypothesize that the addition of antioxidant BMX-010 to perfusion solution, digestion solution and culture medium during islet isolation process, can lead to greater preservation of islet mass and metabolic function, such as improved islet yield, viability, and functional potency. This pilot study will involve up to 10 participants from the islet transplant waiting list at the Clinical Islet Transplant Program. All participants will receive islets isolated with the medication BMX-010. This is to assess the primary safety of BMX-010 on pancreata and islets. BMX-010 will be used only in the islet isolation process, and will not be given to participants as medication.

Conditions

Type 1 Diabetes

Keywords

Type 1 Diabetes; Islet Transplant

Outcome Measures

Primary Outcomes (1)

• Islet yield using BMX-010, compared to current standard islet isolation data

  To assess the safety of treating pancreata using BMX-010 prior to islet transplantation, treated islet isolation data will be measured and recorded, compared to current standard islet isolation data.

  Day -1 pre-transplant (Islet yield will be recorded as standard-of-care routine practice)

Secondary Outcomes (2)

• Islet isolation quantity and quality using BMX-010, compared to current standard islet isolation data

  Day -1 pre-transplant (Islet isolation quantity and quality will be recorded as standard-of-care routine practice)

• AE/SAE morbidity within 1 month post-transplant

  up to 1 month post-transplant

Study Arms (1)

BMX-010 treated islets

EXPERIMENTAL

Islet isolation using BMX-010

Drug: Islet isolation using BMX-010

Interventions

Islet isolation using BMX-010 DRUG

BMX-010 will be used as a supplement in islet isolation process.

Also known as: MnTE-2-PyP

BMX-010 treated islets

Eligibility Criteria

• Age: 18 Years - 68 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• To be eligible the participant must have had type 1 diabetes mellitus (T1DM) for more than 5 years, complicated by at least 1 of the following situations that persist despite intensive insulin management efforts:
• a. Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels \< 3.0 mmol/L, indicated by, 1 or more episodes of severe hypoglycemia requiring third party assistance within 12 months, a Clarke score ≥4, HYPO score ≥1,000, lability index (LI) ≥400 or combined HYPO/LI \>400/\>300.
• b. Metabolic instability, characterized by erratic blood glucose levels that interfere with daily activities and or 1 or more hospital visits for diabetic ketoacidosis over the last 12 months.
• Participants must be capable of understanding the purpose and risks of the study and must sign a statement of informed consent.

You may not qualify if:

• \. History of enrollment in any other islet transplant trials (at the discretion of the investigator).
• \. Severe co-existing cardiac disease, characterized by any one of these conditions: (a) recent (within the past 6months) myocardial infarction; (b) left ventricular ejection fraction \<30%; or (c) evidence of ischemia on functional cardiac exam.
• \. Active alcohol or substance abuse, to include cigarette smoking (must be abstinent for 6 months prior to listing for transplant).
• \. Psychiatric disorder making the subject not a suitable candidate for transplantation, (e.g., schizophrenia, bipolar disorder, or major depression that is unstable or uncontrolled on current medication).
• \. History of non-adherence to prescribed regimens.
• \. Active infection including Hepatitis C, Hepatitis B, HIV, or TB (subjects with a positive PPD performed within one year of enrollment, and no history of adequate chemoprophylaxis).
• \. Any history of, or current malignancies except squamous or basal skin cancer.
• \. BMI \> 35 kg/m2 at screening visit.
• \. Age less than 18 or greater than 68 years.
• \. Measured glomerular filtration rate (GFR) \<60 mL/min/1.73 m2.
• \. Presence or history of macroalbuminuria (\>300 mg/g creatinine).
• \. Clinical suspicion of nephritic (hematuria, active urinary sediment) or rapidly progressing renal impairment (e.g. Increase in serum creatinine of 25% within the last 3-6 months).
• \. Baseline Hb \< 105g/L (\<10.5 g/dL) in women, or \< 120 g/L (\<12 g/dL) in men.
• \. Baseline screening liver function tests outside of normal range, with the exception of uncomplicated Gilbert's Syndrome. An initial LFT panel with any values \>1.5 times the upper limit of normal (ULN) will exclude a patient without a re-test; a re-test for any values between ULN and 1.5 times ULN should be made, and if the values remain elevated above normal limits, the patient will be excluded.
• \. Untreated proliferative retinopathy.

Sponsors & Collaborators

• University of Alberta: lead
• BioMimetix Pharmaceutical, Inc.: collaborator

Study Sites (1)

University of Alberta

Edmonton, Alberta, T6G 2C8, Canada

Location

Related Links

• Clinical Islet Transplant Program at University of Alberta

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Interventions

manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• James Shapiro, MD PhD

  University of Alberta

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 5, 2014
• First Posted: May 29, 2015
• Study Start: August 1, 2014
• Primary Completion: August 1, 2016
• Study Completion: August 1, 2016
• Last Updated: May 11, 2022

Record last verified: 2016-09

Locations

CA (1)